MDxHealth SA, today announced that it has signed a distribution agreement with The European Health Centre Innovation (EHC Innovation) to offer its SelectMDx™ for Prostate Cancer and ConfirmMDx® for Prostate Cancer tests to their urology customers throughout Poland.
Under the terms of the agreement, EHC Innovation will be one of two exclusive distributors of SelectMDx in Poland and the only exclusive distributor of ConfirmMDx. Samples will be sent to MDxHealth's state-of-the-art clinical diagnostic laboratory in Nijmegen, The Netherlands for analysis. EHC Innovation will reimburse MDxHealth for all testing services.
"We are delighted to announce our collaboration with The European Health Centre Innovation which, as part of European Health Center Otwock Hospital, is the most technologically advanced multispecialty diagnostic centre in Poland. We believe that SelectMDx and ConfirmMDx perfectly complement EHC Innovation's existing portfolio of advanced diagnostic tools," commented Dr. Jan Groen, CEO of MDxHealth. "With a strong reputation throughout the region and focus on improving patient care and outcomes, EHC Innovation is an ideal partner to help us raise awareness and expand access to SelectMDx and ConfirmMDx within the urology community."
About SelectMDx for Prostate Cancer
Of the nearly 2 million prostate biopsies performed each year, less than a third find cancer. Most of these men could have avoided a painful and invasive prostate biopsy procedure, with its associated complications and costs. SelectMDx for Prostate Cancer is a proprietary urine-based, molecular diagnostic test that offers a non-invasive 'liquid biopsy' method to assess a man's risk for prostate cancer. SelectMDx helps identify men at increased risk of harbouring aggressive, potentially lethal, prostate cancer who may benefit most from a prostate biopsy and earlier detection. The test delivers a negative predictive value (NPV) of 98% for clinically significant disease, helping to reduce unnecessary MRI procedures and invasive prostate biopsies by approximately 50%, thereby reducing healthcare costs.
About ConfirmMDx for Prostate Cancer
ConfirmMDx for Prostate Cancer is the first epigenetic, and only tissue-based test in the 2016 NCCN Guidelines for early detection of prostate cancer which addresses false negative biopsy concerns. It is the only molecular diagnostic test that provides a very high negative predictive value (NPV) of 96% for clinically significant prostate cancers, and 90% NPV for all prostate cancers, as well as prostate mapping of the test results to help guide repeat biopsies. Each year, more than 1 million American men undergo an invasive prostate biopsy with a negative result, however approximately 30% of those men actually have prostate cancer. The current standard of care for prostate biopsy procedures samples less than 1% of the prostate, leaving men at risk for undetected cancer and leading to a high rate of repeat biopsies, even on cancer-free men. ConfirmMDx for Prostate Cancer helps urologists identify low-risk men who may forego an unnecessary repeat biopsy and high-risk men who may benefit from intervention. To date more than 3,000 urologists have ordered ConfirmMDx on more than 45,000 patients. ConfirmMDx has qualified for Medicare, Medicare Advantage and many private reimbursement plans.
About The European Health Centre Innovation
EHC Innovation (inn4health.com) conducts activities in implementing and providing patients with innovative therapies that can increase the chances of cancer treatment and improve quality and comfort of life. Being a part of the European Health Centre Otwock Hospital which amalgamates tradition with innovation in their entirely renovated facility offering a 96 beds hospital with 4 operating rooms and a speciality focus in Urology, Cardiology, Oncology, Onco-Surgery, General Surgery, Gynaecology and Orthopaedics. The European Health Centre Otwock is one of the most technologically advanced centres in Eastern Europe offering their patient's access to modern diagnostics testing, innovative treatments and one of the most technologically advanced radiology diagnostic centres throughout the region.
MDxHealth (mdxhealth.com0 is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary gene methylation (epigenetic) and other molecular technologies and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy.
Contacts: Jonathan Birt, Chris Welsh, Hendrik Thys - Cameron Standage (PR & IR)
Consilium Strategic Communications
UK: +44(0)20 3709 5701 / US: + 1 917-322-2571 (Rx Communications Group LLC)
This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.
The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx, AssureMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.